

Referencias publicaciones incluidas

1. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial. *JAMA Netw Open*. 2020;3:e2013136, <http://dx.doi.org/10.1001/jamanetworkopen.2020.13136>.
2. Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, Bertasi V, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. *Ann Rheum Dis*. 2020;79:1286-9, <http://dx.doi.org/10.1136/annrheumdis-2020-217712>.
3. Haslak F, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Barut K, Kasapcopur O. Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. *Rheumatol Int*. 2020;40:1423-31, <http://dx.doi.org/10.1007/s00296-020-04645-x>.
4. Sandhu T, Tieng A, Chilimuri S, Franchin G. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. *Can J Infect Dis Med Microbiol*. 2020;2020:8865954, <http://dx.doi.org/10.1155/2020/8865954>.
5. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, Schlesinger N. Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. *J Clin Med*. 2020;9:2961, <http://dx.doi.org/10.3390/jcm9092961>.

6. Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. *Autoimmun Rev.* 2020;19:102566, <http://dx.doi.org/10.1016/j.autrev.2020.102566>.